摘要
目的探讨替格瑞洛联合川芎嗪注射液治疗冠心病心绞痛患者的临床疗效。方法将120例冠心病心绞痛患者按照随机数字表法分为研究组与对照组,各60例。两组均给予替格瑞洛治疗,研究组在此基础上联合川芎嗪注射液治疗。比较两组临床疗效、治疗前后两组心绞痛发作次数及持续时间以及两组左室收缩末期内径、舒张末期内径、左室射血分数、总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、三酰甘油水平。随访1 a,比较两组心血管不良事件发生率。结果研究组治疗总有效率显著高于对照组(P<0.05)。治疗后两组心绞痛发作次数显著少于治疗前(P<0.01),研究组显著少于对照组(P<0.01),两组心绞痛持续时间显著短于治疗前(P<0.01),研究组显著短于对照组(P<0.01)。治疗后两组左室射血分数水平均较治疗前显著升高(P<0.05或0.01),舒张末期内径及左室收缩末期内径水平均较治疗前显著降低(P<0.01),研究组较对照组变化更显著(P<0.05或0.01)。治疗后两组高密度脂蛋白胆固醇水平较治疗前显著升高(P<0.01),总胆固醇、低密度脂蛋白胆固醇及三酰甘油水平均较治疗前显著降低(P<0.01),研究组总胆固醇、低密度脂蛋白胆固醇及三酰甘油水平较对照组变化更显著(P<0.01)。随访1 a,研究组心血管不良事件发生率显著低于对照组(P<0.05)。结论替格瑞洛联合川芎嗪注射液可有效缓解冠心病心绞痛患者的心绞痛情况,改善心功能和血脂水平,有利于预后。
Objective To explore the curative effect of ticagrelor combined with ligustrazine injection in the treatment of angina pectoris of coronary heart disease.Methods A total of 120 patients with coronary heart disease and angina were divided into study group and control group according to the random number table method,with 60 cases in each group.Both groups were treated with ticagrelor,and the study group was treated with ligustrazine injection on this basis.The clinical efficacy of the two groups was compared,and the number and duration of angina pectoris between the two groups before and after treatment were compared.The left ventricular end-systolic dimension(LVESD),left ventricular end-diastolic dimension(LVEDD),left ventricular ejection fraction(LVEF),total cholesterol(TC),high density liptein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C)and triglyceride(TG)levels of the two groups were compared.Follow up for 1 year and compare the incidence of adverse cardiovascular events between the two groups.Results The total effective rate of treatment in the study group was significantly higher than that in the control group(P<0.05).After treatment,the number of angina pectoris in the two groups was significantly less than before treatment(P<0.01),and the study group was significantly less than the control group(P<0.01).The duration of the two groups was significantly shorter than before treatment(P<0.01),and the study group was significantly shorter than the control group(P<0.01).After treatment,the levels of LVEF in the two groups were significantly higher than before treatment(P<0.05 or 0.01),and the levels of LVEDD and LVESD were significantly lower than before treatment(P<0.01).The changes in the study group were more significant than those in the control group(P<0.05 or 0.01).After treatment,the levels of HDL-C in the two groups were significantly higher than before treatment(P<0.01),and the levels of TC,LDL-C and TG were significantly lower than before treatment(P<0.01).The levels of TC,LDL-C and T
作者
李原
卜伟
Li Yuan;Bu Wei(Anyang Second People's Hospital,Anyang 455000,Henan,China)
出处
《临床心身疾病杂志》
CAS
2021年第1期86-89,共4页
Journal of Clinical Psychosomatic Diseases
基金
安阳市科技创新人才项目(编号201708056)。
关键词
冠心病
心绞痛
替格瑞洛
川芎嗪
临床疗效
coronary heart disease
angina pectoris
ticagrelor
ligustrazine
clinical efficacy
